Aloke V. Finn, MD

Education:

1994  B.A. (Political Science), Cum Laude, Kenyon College

2000  M.D. Vanderbilt University School of Medicine

Post Graduate Education and Training:

07/00-06/01     Intern in Medicine, Internal Medicine, Massachusetts General Hospital, Boston, MA, Hasan Bazari MD, PhD

07/01-06/02     Resident in Medicine, Internal Medicine, Massachusetts General Hospital, Boston, MA, Hasan Bazari MD, PhD

07/02-06/04     Clinical Fellow in Cardiology, Cardiology, Massachusetts General Hospital, Boston, MA, Peter Yurchak, MD

07/04-06/05     Fellow in Interventional Cardiology, Massachusetts General Hospital, Boston, MA, Igor Palacios MD

07/05-06/07     Research Fellow in Cardiology, Cardiology, Massachusetts General Hospital, Boston, MA, Ken Bloch, MD

Certifications:

2002             ABIM Internal Medicine

2007/2015    ABIM Cardiovascular Disease

2008/2016    ABIM Interventional Cardiology

Dr. Finn is an interventional cardiologist and internationally recognized expert in the field of vascular biology and vascular device research.  He currently serves as Medical Director and Chief of Research of CVPath and is head of the Institute’s basic and translational research laboratory. He is also an Associate Clinical Professor of Medicine at the University of Maryland, where he serves (part-time) as a cardiologist and interventional cardiologist. 

He has published over 200 peer-reviewed research articles, editorials, and reviews. He is an editorial board member of of Arteriosclerosis, Thrombosis, and Vascular Biology, and PLOS One.  

His research interests are in the area of vascular biology, particularly human vascular disease. He has focused in particular on 1) the molecular mechanisms by which mTOR inhibitors delay endothelial recovery and function after vascular injury; 2) the role of alternative macrophage phenotypes in human atherosclerosis; 3) preclinical research in drug delivery as it relates to both drug-eluting stents and balloons; and mechanisms of injury of COVID-19 on the heart.

Curently he hold grants from the Leduqc Foundation and the National Institues of Health (RECOVER Initiative).  

He obtained his MD from Vanderbilt University in 2000. During medical school, he received a Howard Hughes Medical Student Research Fellowship and studied vascular gene therapy under David Dichek at the University of California at San Francisco. Dr. Finn did his internal medicine, cardiology and interventional cardiology training at the Massachusetts General Hospital in Boston, including two years of vascular biology research with Drs. Herman Gold and Rakesh Jain.  

Atherosclerosis, macrophages, drug-eluting stents, peripheral arterial disease, valvular heart disease

1.  Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, Otsuka F, Gannon RL, Braumann RE, Dickinson MH, Gupta A, Jenkins AL, Lipinski MJ, Kim J, Chhour P, de Vries PS, Jinnouchi H, Kutys R, Mori H, Kutyna MD, Torii S, Sakamoto A, Choi CU, Cheng Q, Grove ML, Sawan MA, Zhang Y, Cao Y, Kolodgie FD, Cormode DP, Arking DE, Boerwinkle E, Morrison AC, Erdmann J, Sotoodehnia N, Virmani R, Finn AV. CD163+ Macrophages Promote Angiogenesis, Vascular Permeability, and Inflammation in Atherosclerosis.  Journal of Clinical Investigation.2018 Mar 1;128(3):1106-1124.1.  

2.  Akahori H, Karmali V, Polavarapu R, Lyle A, Weiss D, Shin E, Husain A, Naqvi N, Van Dam R, Habib A, Choi CU, King AL, Pachua K, Taylor WR, Lefer D, Finn AV.  CD163 TWEAK Interaction Regulates Tissue Regeneration After Ischemic Injury.  Nat Comm. 2015. Aug 5;6:7792.  PMID:26242746.

3.  Finn AV, Virmani R.  The Clinical Challenge of Disappearing Stents.  The Lancet.  2016 Feb 6;387:501-512.  PMID: 26597772.

4.  Mori H, Finn AV, Atkinson JB, Lutter C, Narula J, Virmani R. Calcified Nodule:

An Early and Late Cause of In-Stent Failure. JACC Cardiovasc Interv. 2016 Jun 6.

PMID: 27318841.

5.  Harari E, Guo L, Smith SL, Paek KH, Fernandez R, Sakamoto A, Mori H, Kutyna

MD, Habib A, Torii S, Cornelissen A, Jinnouchi H, Gupta A, Kolodgie FD, Virmani

R, Finn AV. Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase

Improves Endothelial Permeability in Drug-Eluting Stents-Brief Report.

Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2217-2224.  PMID: 30026269.

5.  Jaber WA, Finn AV. Intrastent Tissue Prolapse and Late Cardiac Events:

Innocent Bystander or Culprit? JACC Cardiovasc Interv. 2016 Jul 25;9(14):1508-9.

PMID: 27478120.

6.  Koppara T, Sakakura K, Pacheco E, Cheng Q, Zhao X, Acampado E, Finn AV, Barakat M, Maillard L, Ren J, Deshpande M, Kolodgie FD, Joner M, Virmani R.

Preclinical evaluation of a novel polyphosphazene surface modified stent. Int J

Cardiol. 2016 Nov 1;222:217-25. doi: 10.1016/j.ijcard.2016.07.181. Epub 2016 Jul

7. PMID: 27497098.

7.  Finn AV, Virmani R. Biodegradable polymer drug-eluting stents:

non-inferiority waiting for superiority? Lancet. 2016 Nov 26;388(10060):2567-2568.  PMID: 27806901.

8.  Lutter C, Mori H, Yahagi K, Ladich E, Joner M, Kutys R, Fowler D, Romero M,  Narula J, Virmani R, Finn AV. Histopathological Differential Diagnosis of Optical

Coherence Tomographic Image Interpretation After Stenting. JACC Cardiovasc

Interv. 2016 Dec 26;9(24):2511-2523.  PMID: 27889345.

9.  Mori H, Kutys R, Romero M, Virmani R, Finn AV. Stenting of Spontaneous

Coronary Artery Dissection From a Pathological Point of View. Circ Cardiovasc

Interv. 2016 Dec;9(12). PMID: 27895071.

10.  Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, Virmani R.

Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular

Calcification in Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2017

Feb;37(2):191-204. Review.  PMID: 27908890; PubMed Central PMCID: PMC5269516.

11.  Mori H, Lutter C, Yahagi K, Harari E, Kutys R, Fowler DR, Ladich E, Joner M,

Virmani R, Finn AV. Pathology of Chronic Total Occlusion in Bare-Metal Versus

Drug-Eluting Stents: Implications for Revascularization. JACC Cardiovasc Interv.

2017 Feb 27;10(4):367-378.  PMID: 28161258.

12.  Mori H, Harari E, Torii S, Virmani R, Finn AV. Evaluating the utility of

markers of thromboxane activity and oxidative stress in cardiovascular risk

prediction. Coron Artery Dis. 2017 Jun;28(4):275-277.  PMID: 28225389.

13.  Guo L, Harari E, Virmani R, Finn AV. Linking Hemorrhage, Angiogenesis,

Macrophages, and Iron Metabolism in Atherosclerotic Vascular Diseases.

Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):e33-e39.  PMID: 28330947.

14.  Mori H, Kutys R, Romero M, Virmani R, Finn AV. Metallic Coronary Stents: Is There a Relationship Between Stent Fracture and Hypersensitivity? JACC Cardiovasc Interv. 2017 Jun 12;10(11):1175-1177. PMID: 28527770.

15.  Yahagi K, Ladich E, Kutys R, Mori H, Svensson LG, Mack MJ, Herrmann HC, Smith CR, Leon MB, Virmani R, Finn AV. Pathology of balloon-expandable transcatheter aortic valves. Catheter Cardiovasc Interv. 2017 Jun 1. PMID: 28569053.